Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  MAUNA KEA TECH    MKEA   FR0010609263

MAUNA KEA TECH (MKEA)

272
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

MAUNA KEA TECH : MAUNA KEA TECHNOLOGIES ANNOUNCES CELLVIZIO'S VERY STRONG PRESENCE AT THREE MAJOR GASTROENTEROLOGY CONFERENCES IN THE USA, EUROPE AND JAPAN

10/15/2013 | 01:09pm US/Eastern
MAUNA KEA TECHNOLOGIES ANNOUNCES CELLVIZIO'S VERY STRONG PRESENCE AT THREE MAJOR GASTROENTEROLOGY CONFERENCES IN THE USA, EUROPE AND JAPAN 30 presentations dedicated to the benefits of optical biopsy at the same time on 3 continents Paris, Berlin, Tokyo, San Diego, October 15, 2013 - Mauna Kea Technologies (NYSE Euronext: MKEA FR0010609263), leader in the optical biopsy market and maker of Cellvizio, the fastest way to see cancer, today announced its strong participation in 3 major congresses around the world: the United European Gastroenterology Week (UEGW) in Berlin, the annual congress of the American College of Gastroenterology in San Diego, and the Japanese Digestive Disease Week in Tokyo. United European Gastroenterology Week (UEGW), Berlin, 12 to 16 October 2013

More than 20 study results on patient management optimization thanks to Cellvizio will be presented at this congress hosting 14,000 attendees, the most important and prestigious in gastroenterology in Europe. A large portion of these results will be on pancreatic cyst management with the AQ-Flex probe, which was recently cleared by FDA and launched in the USA.
A large number of attendees could also see a live demonstration of Cellvizio in the management of Barrett's Esophagus performed by Pr. Emmanuel Coron from CHU Nantes, France, from the Sana-Klinikum Lichtenhagen, where Cellvizio was used to orient the patient's therapeutic options.

Japanese Digestive Disease Week (JDDW), Tokyo, 8 to 12 October 2013

With more than 20 000 participants, this congress provided a strong exposure for Cellvizio to the Japanese market, a pioneering and very important one for digestive endoscopy. Several physicians from Japan and other Asian countries presented orally their results with Cellvizio on Asian populations, in particular on pancreatic cyst management.

Annual Congress of the American College of Gastroenterology (ACG), San Diego, 13 to 15 October 2013

Mauna Kea Technologies also has a strong presence at the ACG meeting, one of the most important for gastroenterology in the USA, the most important market for the Company today. Optical Biopsy was in the spotlight with more than 10 presentations as well as a hands-on training session on Cellvizio. Physicians could also discover how easy optical biopsy interpretation was thanks to a dedicated station.
Sacha Loiseau, CEO of Mauna Kea Technologies, declared: « The simultaneous presence of Mauna Kea Technologies on these 3 major gastroenterology congresses in Europe, Asia and the United-States, once more underlines the broad reach and the growing recognition of the value that Cellvizio optical biopsy brings to patients, physicians and healthcare systems around the world ».

About Mauna Kea Technologies

Mauna Kea Technologies is a global firm specializing in medical equipment used to carry out optical biopsies, and is market leader in endomicroscopy. The company designs, develops and sells innovative imaging tools that can detect cellular abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. Its flagship product, Cellvizio®, a confocal endomicroscopy system that uses a mini-probe, provides doctors and researchers with high-resolution cellular images of internal tissues. Large-scale, international multi-center clinical trials have demonstrated Cellvizio's ability to help physicians to more accurately detect early signs of disease and make immediate treatment decisions. Cellvizio was designed to help physicians make diagnoses, treat patients more effectively and reduce hospital costs, and is compatible with most types of endoscope. It has

1

received 510(k) authorization from the US Food and Drug Administration and the CE mark in Europe for use in gastrointestinal and pulmonary equipment.

For more information on Mauna Kea Technologies, please visit www.maunakeatech.com

Mauna Kea Technologies

Eric Cohen

V ice-President Finance

Tel: +33 (0)1 70 08 09 70

investor-vpf@maunakeatech.com

France and Europe

ALIZE RP

Caroline Carmagnol / Christian Berg

Tel: +33 (0)6 64 18 99 59 / +33 (0)1 70 22 53 86 caroline@alizerp.com / christian@alizerp.com

NEWCAP

Investor Relations & Financial Communications

Florent Alba / Pierre Laurent Tel: +33 (0)1 44 71 94 94 maunakea@newcap.fr

2

distributed by
Latest news on MAUNA KEA TECH
21h ago MAUNA KEA TECH : French High Authority for Health OKs Optical Endomicroscopy for..
1d ago MAUNA KEA TECH : ologies : Reports Cellvizio Study Results
4d ago MAUNA KEA TECH : Physicians using optical biopsy with Cellvizio discover a new d..
10/16 MAUNA KEA TECH : ologies : Posts Results of Cellvizio
10/16 MAUNA KEA TECH : French High Authority for Health Approves Optical Endomicroscop..
10/13 MAUNA KEA TECH : Success and strong attendance for Cellvizio at the annual chine..
10/10MAUNA KEA TECHNOLOGIES SAS : quaterly sales release
09/23 MAUNA KEA TECH : Major Success for Cellvizio at the EUS 2014 Conference
08/28 MAUNA KEA TECH : Financial Results for Half Year 2014
08/07 MAUNA KEA TECH : ologies : Secures 510(K) Regulatory OK from FDA for Cellvizio S..
Advertisement
Chart
Duration : Period :
MAUNA KEA TECH Technical Analysis Chart | MKEA | FR0010609263 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF